molmir
Category: AI in Biotech / Drug Discovery
AI molecular visualization platform aimed at accelerating drug discovery. molmir was founded in 2022. The company is led by Eiichiro Mori. Based in Kashihara, Nara, Japan. Total funding raised: ~$3.2M (¥480M). Latest round: Series A. Key investors include Mitsubishi UFJ Capital, Real Tech Holdings, Ikeda Senshu Capital, KTX Corporation, UntroD Capital Japan, BP Capital, Nanto Capital Partners, Higin Capital.
- Founded
- 2022
- Headquarters
- Kashihara, Nara, Japan
- Total funding
- ~$3.2M (¥480M)
Value proposition
Molmiru’s AI molecular visualization platform enables researchers to interact with and analyze molecular structures more efficiently, accelerating drug discovery.
Products and solutions
AI molecular visualization platform
Industries served
Biotech, Drug Discovery
Technology advantage
Its AI-driven molecular visualization platform offers domain-specific modeling for biotech, leveraging early-stage Japanese venture interest and corporate venture backing.
Key partnerships
Nara Medical University (joint research course: Laboratory of Molecular Dynamics and Drug Discovery), OrganoTherapeutics (strategic R&D collaboration for Parkinson's disease)
Major milestones
Identified hit compound targeting TDP-43 (ALS causative protein) via CHEmir/MAGmir molecular-dynamics platform, Selected for Nakanoshima Qross Drug Discovery Program (August 2025), Awarded Deep Tech Venture of the Year 2025, Nominated for Direct Flight 2025 Medical Startups Global Acceleration Program, Raised ¥300M Series A round (April 2026)
Market positioning
AI drug discovery tooling startup targeting pharmaceutical and biotech companies in the nascent Japanese biotech AI ecosystem.
About Eiichiro Mori
Associate Professor at Nara Medical University; previously at Nara Medical University Hospital and University of Texas Southwestern Medical Center
Latest news about molmir
More AI in Biotech / Drug Discovery companies
Official website: https://www.molmir.co.jp/en/